Jade Biosciences, Inc. (JBIO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Jade Biosciences, Inc. (JBIO) has a cash flow conversion efficiency ratio of -0.123x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-22.12 Million) by net assets ($179.35 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Jade Biosciences, Inc. - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Jade Biosciences, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Jade Biosciences, Inc. carry for a breakdown of total debt and financial obligations.
Jade Biosciences, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jade Biosciences, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mount Gibson Iron Limited
F:FWQ
|
0.169x |
|
Bravo Mining Corp
V:BRVO
|
-0.005x |
|
Runway Growth Finance Corp
NASDAQ:RWAY
|
-0.007x |
|
Formosan Union Chemical Corp
TW:1709
|
0.008x |
|
Clearview Wealth Ltd
AU:CVW
|
-3.782x |
|
Taiwan Tea Corp
TW:2913
|
0.004x |
|
Shandong Molong Petroleum Machinery Company Limited
F:PXI
|
0.088x |
|
Tigaraksa Satria Tbk
JK:TGKA
|
0.129x |
Annual Cash Flow Conversion Efficiency for Jade Biosciences, Inc. (2020–2024)
The table below shows the annual cash flow conversion efficiency of Jade Biosciences, Inc. from 2020 to 2024. For the full company profile with market capitalisation and key ratios, see JBIO market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $76.43 Million | $-71.20 Million | -0.931x | -79.57% |
| 2023-12-31 | $109.46 Million | $-56.78 Million | -0.519x | -68.05% |
| 2022-12-31 | $126.74 Million | $-39.12 Million | -0.309x | -94.24% |
| 2021-12-31 | $172.42 Million | $-27.40 Million | -0.159x | +94.05% |
| 2020-12-31 | $2.94 Million | $-7.86 Million | -2.672x | -- |
About Jade Biosciences, Inc.
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. The company develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. It also develops JADE201 and JADE-003, which are in preclinical development stage. Ja… Read more